Amy Heidersbach
YOU?
Author Swipe
View article: A novel, high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways <i>ex vivo</i> and <i>in vivo</i>
A novel, high-density CRISPR activation platform for mapping cancer dependencies and resistance pathways <i>ex vivo</i> and <i>in vivo</i> Open
CRISPR activation (CRISPRa) enables precise, locus-specific upregulation of gene expression, offering potential for both ex vivo and in vivo applications. However, the lack of scalable, high-coverage tools has limited its use in comprehens…
View article: COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway Open
Aberrant activation of the mitogen-activated protein kinase (MAPK) cascade promotes oncogenic transcriptomes. Despite efforts to inhibit oncogenic kinases, such as BRAFV600E, tumor responses in patients can be heterogeneous and limited by …
View article: Towards designing improved cancer immunotherapy targets with a peptide-MHC-I presentation model, HLApollo
Towards designing improved cancer immunotherapy targets with a peptide-MHC-I presentation model, HLApollo Open
View article: Chemically-inducible CRISPR/Cas9 circuits for ultra-high dynamic range gene perturbation
Chemically-inducible CRISPR/Cas9 circuits for ultra-high dynamic range gene perturbation Open
CRISPR/Cas9 technologies provide unique capabilities for modeling disease and understanding gene-to-phenotype connections. In cultured cells, chemical-mediated control of Cas9 activity can limit off-target effects and enable mechanistic st…
View article: HLApollo: Towards designing improved cancer immunotherapy targets with a superior peptide-MHC-I presentation model
HLApollo: Towards designing improved cancer immunotherapy targets with a superior peptide-MHC-I presentation model Open
Based on the success of cancer immunotherapy, personalized cancer vaccines have recently emerged as the vanguard of oncology treatment. Because antigen presentation on MHC class I (MHC-I) is key to the adaptive immune response to cancerous…
View article: Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types
Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types Open
The broad application of precision cancer immunotherapies is limited by the number of validated neoepitopes that are common among patients or tumor types. To expand the known repertoire of shared neoantigen–human leukocyte antigen (HLA) co…
View article: HLApollo: Towards designing improved cancer immunotherapy targets with a superior peptide-MHC-I presentation model
HLApollo: Towards designing improved cancer immunotherapy targets with a superior peptide-MHC-I presentation model Open
Based on the success of cancer immunotherapy, personalized cancer vaccines have recently emerged as the vanguard of oncology treatment. Because antigen presentation on MHC class I (MHC-I) is key to the adaptive immune response to c…
View article: A versatile, high-efficiency platform for CRISPR-based gene activation
A versatile, high-efficiency platform for CRISPR-based gene activation Open
CRISPR-mediated transcriptional activation (CRISPRa) is a powerful technology for inducing gene expression from endogenous loci with exciting applications in high throughput gain-of-function genomic screens and the engineering of cell-base…
View article: HLApollo: A superior transformer model for pan-allelic peptide-MHC-I presentation prediction, with diverse negative coverage, deconvolution and protein language features
HLApollo: A superior transformer model for pan-allelic peptide-MHC-I presentation prediction, with diverse negative coverage, deconvolution and protein language features Open
Antigen presentation on MHC class I (MHC-I) is key to the adaptive immune response to cancerous cells. Computational prediction of peptide presentation by MHC-I has enabled individualized cancer immunotherapies. Here, we introduce HLApollo…
View article: Discovery of prevalent, clinically actionable tumor neoepitopes via integrated biochemical and cell-based platforms
Discovery of prevalent, clinically actionable tumor neoepitopes via integrated biochemical and cell-based platforms Open
Summary Strategies for maximizing the potency and specificity of cancer immunotherapies have sparked efforts to identify recurrent epitopes presented in the context of defined tumor-associated neoantigens. Discovering these “neoepitopes” c…
View article: Author Correction: Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance
Author Correction: Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance Open
View article: Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance
Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance Open
View article: A versatile, high-efficiency platform for CRISPR-based gene activation
A versatile, high-efficiency platform for CRISPR-based gene activation Open
CRISPR-mediated transcriptional activation (CRISPRa) is a powerful technology for inducing gene expression from endogenous loci with exciting applications in high throughput gain-of-function genomic screens and the engineering of cell-base…
View article: A novel CRISPR activation mouse enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.
A novel CRISPR activation mouse enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Open
CRISPR technologies have advanced cancer modelling in mice, but CRISPR activation (CRISPRa) methods have not been thoroughly exploited in this context. Here we establish a CRISPRa mouse (dCas9a-SAMKI/+) for inducing gene express…
View article: Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes
Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes Open
Significance Statement Two variants of circulating APOL1, G1 and G2, protect against subspecies of Trypanosoma brucei infection, but concurrently confer a greater risk of CKD. Little is known about the topology of APOL1 in HDL particles or…
View article: Publisher Correction: Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics
Publisher Correction: Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics Open
View article: Disruption of IRE1α through its kinase domain attenuates multiple myeloma
Disruption of IRE1α through its kinase domain attenuates multiple myeloma Open
Significance Multiple myeloma (MM) is a lethal malignancy arising from plasma cells. MM cells experience endoplasmic reticulum (ER) stress due to immunoglobulin hyperproduction. The ER-resident sensor IRE1α mitigates ER stress by expanding…
View article: Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility Open
View article: Disruption of IRElα through its Kinase Domain Attenuates Multiple Myeloma
Disruption of IRElα through its Kinase Domain Attenuates Multiple Myeloma Open
Multiple myeloma (MM) arises from malignant immunoglobulin-secreting plasma cells and remains an incurable, often lethal disease despite recent therapeutic advances. The unfolded-protein response sensor IRE1α supports protein secretion by …
View article: MicroRNA-155 Reinforces HIV Latency
MicroRNA-155 Reinforces HIV Latency Open